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It is a very refreshing idea to use clinical data and
health outcomes to decide how to best diagnose Chronic
Obstructive Pulmonary Disease (COPD). Therefore we
read the article by Güder et al. [1] with great interest.
However, upon reading the article in more detail we
developed reservations about the criteria used.
The authors started with 405 patients aged ≥65 years
with a general practitioner’s (GP) diagnosis of COPD. A
GP and a chest physician subsequently decided that 37%
did not have COPD but they were still treated as if they
had COPD. In fact, the percentage of not-COPD sub-
jects receiving inhaled corticosteroids was almost as high
as in those with expert panel (EP) COPD (EP COPD+).
As there was a definite COPD bias in the selection of
subjects, the EP-COPD negative patients are not an ad-
equate control group.
A large mix of criteria was used to diagnose EP-
COPD+. It is impossible to reconstruct how the diag-
nosis was adjudicated. There does not seem to have
been any weighting of symptoms, signs, or measure-
ment results. In fact, FEV1/FVC, FEV1 percentage of
predicted, RV/TLC were used, but no information is
provided what criteria were applied in diagnosing EP-
COPD+. Presumably the GP and chest physician adju-
dicated a diagnosis without a predefined algorithm,
nor blinded to the assessment of their counterpart. It
is to be expected that the judgment of the chest phys-
ician would predominate, because many of the mea-
surements are not part and parcel of a GP’s routine.
In that respect the fall in Cohen’s kappa upon re-
assessing the EP-COPD diagnosis suggests that agree-
ment between chest physicians is not optimal.* Correspondence: pquanjer@xs4all.nl
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reproduction in any medium, provided the orThe diagnosis of COPD was based on pulmonary func-
tion indices, using unspecified cutoff criteria and an un-
known reference equation. Pulmonary function criteria
were probably pivotal in establishing the diagnosis.
Maintaining a diagnosis based on arbitrary lung function
criteria rather than redefining EP-COPD + by applying
other pulmonary function criteria and prediction equa-
tions is a flawed approach, particularly when studying
how the diagnosis of COPD is affected by such criteria
and prediction equations. The exclusive use of one set of
arbitrary pulmonary function criteria for establishing a
diagnosis precludes studying how the diagnosis is
affected by other criteria.
The use of percent of predicted, for example for FEV1,
is also flawed as the scatter is not proportional to the
predicted value; this creates an age, sex, height and eth-
nic group related bias [2-6]. Stanojevic [6] was the first
to show that in adults the scatter increases with age.
This means that the lower limit of normal (LLN) derived
from conventional regression equations cannot be
derived from predicted minus 1.64RSD, because the
RSD varies with age. The use of z-scores using Stanoje-
vic equations [6] is the method of choice, because z-
scores are free of bias. The only problem is that the age
is limited to 80 years; this will be resolved when the Glo-
bal Lungs Initiative publishes its 3-95 year predicted
values (www.lungfunction.org).
The number of co-morbidities in elderly subjects is
very great and this makes it very difficult to tease out a
clinical diagnosis of COPD. Cox regression (hazard
ratios) should not be used as a basis for comparisons of
risk among the various definitions of COPD, because
these differ in their reference groups and because the ex-
pert panel would have had access to relevant informa-
tion concerning likelihood of the tested outcomes.
Moreover, the analyses make no adjustment for con-
founders such as age, smoking habit and male sex which
will affect the tested outcomes and may vary between
the groups.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://respiratory-research.com/content/13/1/61Finally, including criteria to which a GP does not have
access, such as RV/TLC, makes establishing a diagnosis
of COPD out of reach of GPs.
Authors’ response
Gülmisal Güder, Stefan Störk, Arno W Hoes and Frans
H Rutten.
We thank Quanjer and colleagues for their insightful
comments regarding our article [1]. Some points, how-
ever, deserve further clarification. The critique of current
COPD definitions was not intended to specifically ad-
dress the GOLD guidelines or the lower limit of normal
(LLN) approach, but was a general caveat to base the
diagnosis onto one single ratio derived from pulmonary
function testing (PFT), ie FEV/FVC. Using the Stanoje-
vic equation [6] as proposed by Quanjer might indeed
increase the specificity of the LLN definition, but it will
not improve the sensitivity since the LLN approach as
well as the GOLD definition fails to acknowledge false
negative spirometric test results. Important diagnostic
needs will still remain unsolved. E.g., how should we
classify patients who – according to the GOLD or LLN
definition – are (borderline) normal and have abnormal-
ities at diffusion testing or RV/TLC ratio, especially
those with a smoking history and symptoms.
All 405 patients in our study had a GP’s diagnosis of
COPD and were treated accordingly. The study team did
not attempt to modify the pulmonary treatment. We
also did not exclude patients with co-morbidities as this
might provoke selection bias, nor did we consider
healthy never-smokers as controls, since they hardly
pose diagnostic problems in daily routine. According to
the GOLD definition, about 60% of all patients suffered
from COPD, and about 40% depending on the type of
LLN definition. Hence, the challenge was not only to dif-
ferentiate true positive from false positive COPD
patients but to also consider the possibility of false nega-
tives. We therefore used an expert diagnosis of a pulmo-
nologist and GP (validated internally and externally) as
the reference standard. We agree that this is not a per-
fect standard. However, we are still convinced that an
experienced physician will outperform a single and ra-
ther rigid mathematical model in the complex process of
integrating very heterogeneous informations from vari-
ous tests, including other PFT results as well as signs
and symptoms. For many diseases that lack an irrefut-
able single test as a reference, the use of an expert panel
(using all diagnostic information) is an excepted alterna-
tive, e.g. in heart failure.
Furthermore, although the LLN approach is regarded
more “physiological” than the GOLD definition, since it
considers age-, sex-and height-dependent cut-off values
of FEV1/FVC, the present real-world cohort illustrates
that the LLN definition is not widely used by GPs todiagnose COPD. One reason for this reluctance might
be the lack of consistency between different LLN equa-
tions [7]. In a recent review, the shortcomings of
population-derived LLN equations were thoroughly dis-
cussed and the need of more studies with longitudinal
data to identify markers of COPD diagnosis and progno-
sis was emphasized [8].
In our prospective cohort study the two most import-
ant PFT parameters for identifying a positive expert
COPD diagnosis besides FEV1/FVC ratio were FEV1 as
% predicted and RV/TLC. Our proposed diagnostic algo-
rithm is not yet validated; however, it is the very first
mathematical attempt that considers plausibility check-
ing of a COPD diagnosis.
We agree with Quanjer and colleagues that in our Cox
regression analysis comparing expert COPD vs. the LLN
or GOLD definition information bias may be a concern
and it may explain the slightly superior point estimate of
the expert diagnosis. However, since cut-off based defini-
tions do not consider other information than provided
in the equation, multivariable adjustment is not justified
to test the prognostic capacity of different LLN defini-
tions as suggested by the authors. Instead, and consist-
ent with general clinical practice, we advocate to
deliberately use otherwise neglected clinical information
for diagnosis and decision making.
In general, the goal of making a diagnosis is to define
a certain population that may benefit from certain ther-
apies. The ideal diagnostic perfectly identifies the sub-
group sensitive to therapy, and accurately predicts
relevant clinical outcomes (e.g., exacerbations, hospitali-
zations, mortality). Our results remind us of the useful-
ness of the clinical view, including signs and symptoms.
Moreover, we provide some evidence that bodyplethys-
mographic measurements and diffusion testing is useful
to decide whether a patient has COPD when spirometry
results are indifferent. Maybe it is time to realize that
the definition of COPD needs to include some ‘clinical
items’, as nearly all definitions of diseases in medicine in-
clude clinical aspects of patients.
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